PV Bulletin

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The FDA has approved Rasonque (daraxonrasib), a novel treatment for metastatic pancreatic adenocarcinoma, enhancing survival outcomes for patients.

Primary source: Inspections and Compliance

PV Impact Brief

Urgency: HighConfidence: high

What changed

Approval of Rasonque requires updates to product labeling to include new indications and safety information following its designation as a Breakthrough Therapy and Orphan Drug.

Why it matters

This approval introduces a significant therapeutic option for a historically difficult-to-treat cancer, potentially enhancing survival and quality of life for patients with metastatic pancreatic adenocarcinoma.

Action needed

Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.

Relevant for
Labeling LeadRegulatory Intelligence Lead
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 26, 2026

Full briefing

Practical implication

Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.

On August 26, 2026, the FDA approved Rasonque (daraxonrasib) as a RAS inhibitor for adults with metastatic pancreatic adenocarcinoma who have undergone prior systemic treatment or are unsuitable for multiagent therapy. The approval arose from a clinical trial showing a median overall survival improvement from 6.7 to 13.2 months compared to standard chemotherapy.

What changed: Approval of Rasonque requires updates to product labeling to include new indications and safety information following its designation as a Breakthrough Therapy and Orphan Drug.

Why it matters: This approval introduces a significant therapeutic option for a historically difficult-to-treat cancer, potentially enhancing survival and quality of life for patients with metastatic pancreatic adenocarcinoma.

Practical implication: Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.

View original source

  • Source: FDA - What's New Drugs RSS
  • Published at source: 2026-08-26T00:00:00.000Z
  • Discovered by monitor: 2026-08-26T22:31:10.393Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling#Safety Signals#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicANSM · France · Updated Sep 7, 2026Translated From French

Injunction No. 2026-DM-031-INJ Regarding Ortho Partner Establishment in Montreuil

Urgency: High

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward